Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer

Siva P. Raman, Sushanth Reddy, Matthew J. Weiss, Lindsey L. Manos, John L. Cameron, Lei Zheng, Joseph M. Herman, Ralph H. Hruban, Elliot K. Fishman, Christopher L. Wolfgang

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Pancreatic adenocarcinoma is a rapidly progressive malignancy characterized by its tendency for early metastatic spread. MDCT is the primary diagnostic modality for the preoperative staging of patients with pancreatic cancer, with an accuracy established in multiple studies. However, for a variety of reasons, there is often a prolonged interval between staging MDCT and the surgical intervention. This study examines the relationship between the interval between imaging and surgery and the accuracy of MDCT in determining the presence or absence of metastatic disease at surgery in patients with pancreatic cancer.

MATERIALS AND METHODS: Patients were identified who had undergone surgery for pancreatic cancer at our institution with a dedicated preoperative pancreas-protocol MDCT performed in our department. Findings from the preoperative MDCT report were correlated with the operative findings, as well as the time between imaging and surgery.

RESULTS: Two hundred ninety-two MDCT scans were performed on 256 patients who underwent exploration for pancreatic adenocarcinoma. The patients had a median age of 67 years (range, 30-95 years), and 51.6% (132/256) were male. The median time between MDCT and surgical exploration was 15.5 days (range, 1-198 days). MDCT correctly predicted the absence of metastatic disease at surgery in 233 of 274 (85.0%) studies. MDCT was more accurate in predicting the absence of metastatic disease if the study was performed within 25 days of surgery than it was if the study was performed within more than 25 days of surgery (89.3% vs 77.0%; p = 0.0097). Furthermore, regression models showed that the negative predictive value of a given MDCT significantly decreased after approximately 4 weeks.

CONCLUSION: MDCT is an accurate method to stage patients with pancreatic cancer, but its accuracy in excluding distant metastatic disease depreciates over time. Patients should undergo a repeat MDCT within 25 days of any planned definitive operative intervention for pancreatic cancer to avoid unexpectedly finding metastatic disease at surgery.

Original languageEnglish (US)
Pages (from-to)W37-W42
JournalAJR. American journal of roentgenology
Volume204
Issue number1
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • MDCT
  • metastases
  • pancreatic adenocarcinoma
  • pancreatic cancer
  • staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this